Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Dr Serena Lucotti, who has been awarded 'Italy Made Me' prize for her DPhil project.

Dr Serena Lucotti, a postdoctoral researcher in the Mechanisms of Metastasis research group, has been awarded an Italy Made Me prize for her DPhil project entitled: ‘Targeting prostanoid biosynthesis during metastasis: the therapeutic potential of aspirin and beyond’.

During her DPhil, Serena studied the effect of aspirin and other anti-platelet drugs on cancer metastasis, which led her to discover a novel platelet signalling pathway that supports tumour cell dissemination through the bloodstream. Her work identifies new targets and therapeutic opportunities for the prevention of metastasis in cancer patients.

Serena received her award from the Ambassador, Raffaele Trombetta, at a ceremony at the Italian Embassy on 4th September. 

The Italy Made Me award recognises UK-based Italian researchers who received part of their training in Italy. There are prizes for innovative research in three categories: Life Sciences, Physical and Engineering Sciences, Social Sciences and Humanities. It is coordinated by the Italian Embassy in London, in collaboration with Il Circolo, the “Association of Italian Scientists in the United Kingdom” (AISUK) and other Italian academic associations in the UK.

Similar stories

MP Anneliese Dodds tours Oxford cancer research

Anneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the University of Oxford to learn more about the impactful work happening across departments in the field of cancer research.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana has found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Dr Lennard Lee awarded ACP McElwain Prize for contributions to medical oncology

Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.

Further funding secured to hunt out cancer using innovative radiotherapy techniques

Initial success leads to new award for Oxford researcher pushing forward new cancer-hunting radiotherapy despite lockdown.